EP1253142A1 — Compounds exhibiting thrombopoietin receptor agonism
Assigned to Shionogi and Co Ltd · Expires 2002-10-30 · 24y expired
What this patent protects
Pharmaceutical compositions exhibiting thrombopoietin receptor agonism, which contain as the active ingredient compounds of the general formula (I): X 1 -Y 1 -Z 1 -W 1 prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them wherein X 1 is optionally…
USPTO Abstract
Pharmaceutical compositions exhibiting thrombopoietin receptor agonism, which contain as the active ingredient compounds of the general formula (I): X 1 -Y 1 -Z 1 -W 1 prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them wherein X 1 is optionally substituted aryl, optionally substituted heteroaryl, or the like; Y 1 is -NR A CO-(CH 2 ) 0-2 - (wherein R A is hydrogen or the like) or the like; Z 1 is optionally substituted phenylene or the like; and W 1 is a group of the general formula (II): (II) (wherein R 1 , R 2 , R 3 and R 4 are each independently hydrogen, optionally substituted lower alkyl, or the like; and the broken line represents the presence or absence of a bond), or the like.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.